We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Oral and Intravenous Ramosetron During Laparoscopic Cholecystectomy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2009 by Seoul National University Bundang Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01041183
First Posted: December 31, 2009
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Seoul National University Bundang Hospital
  Purpose
Patients undergoing general anesthesia for laparoscopic cholecystectomy have a high risk of postoperative nausea and vomiting (PONV). The investigators investigated the effect of oral and IV ramosetron on PONV prophylaxis after laparoscopic cholecystectomy.

Condition Intervention
Nausea Vomiting Laparoscopic Cholecystectomy Drug: intravenous ramosetron Drug: oral ramosetron Drug: oral and IV ramosetron

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by Seoul National University Bundang Hospital:

Primary Outcome Measures:
  • Incidence of PONV [ Time Frame: postoperative 0-48 h ]

Estimated Enrollment: 120
Study Start Date: November 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: group I
0.3 mg IV ramosetron
Drug: intravenous ramosetron
0.3 mg IV ramosetron (group I)
Active Comparator: group II
0.1 mg oral ramosetron
Drug: oral ramosetron
0.1 mg oral ramosetron (group II)
Active Comparator: group III
0.1 mg oral ramosetron plus 0.3 mg IV ramosetron
Drug: oral and IV ramosetron
0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ASA I-II patients, 25-65 years, electivelaparoscopic cholecystectomy under general anesthesia

Exclusion Criteria:

  • GI disease, pregnant or menstruating, history of motion sickness and/or postoperative emesis, antiemetics within 24 h before surgery
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01041183


Contacts
Contact: Jung-Hee Ryu, Ph.D 82-31-787-7497 jinaryu@lycos.co.kr

Locations
Korea, Republic of
Jung-Hee Ryu Recruiting
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
Contact: Jung-Hee Ryu, Ph.D    82-31-787-7497    jinaryu@lycos.co.kr   
Sponsors and Collaborators
Seoul National University Bundang Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier: NCT01041183     History of Changes
Other Study ID Numbers: nasea-LC
First Submitted: December 30, 2009
First Posted: December 31, 2009
Last Update Posted: October 12, 2017
Last Verified: November 2009

Keywords provided by Seoul National University Bundang Hospital:
Oral plus IV ramosetron may be more effective than
IV ramosetron and oral ramosetron for the prophylaxis of
PONV after laparoscopic cholecystectomy

Additional relevant MeSH terms:
Vomiting
Signs and Symptoms, Digestive
Signs and Symptoms
Ramosetron
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action